Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Recruiting · NCT07534033 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include: Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment? Participants will: Take LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions
Who can take part
Inclusion criteria
- Histologically confirmed newly diagnosed patients
- ECOG performance status 0-1
- Age ≥18 years
- Measurable lesions (RECIST v1.1)
- Organ function meeting the requirements for chemotherapy and immunotherapy.
Exclusion criteria
- Including active autoimmune diseases
- Recent use of immunosuppressants
- Interstitial lung disease
- Presence of other malignancies
- History of immunotherapy
- Active infection
- Pregnancy or drug allergies
Where it is running
1 location listed.
- Zhu Jiang Hospital of Southern Medical University - Guangzhou, China